

TESTA, HURWITZ & THIBEAULT, LLP

ATTORNEYS AT LAW

HIGH STREET TOWER
125 HIGH STREET

BOSTON, MASSACHUSETTS 02110

OFFICE (617) 248-7000

FAX (617) 248-7100

TELECOPY COVER SHEET

Equipment Operator Contact Number: 617-248-7240. Please call if you do not receive all the pages.

Date: April 23, 2003

TO: **Name:** Examiner Joseph F. Murphy, Ph.D.
Company: USPTO
Telephone: (703) 305-7245
Fax: (703) 746-5164

FROM: **Sender:** Patrick R. H. Waller, Ph.D.
Telephone: (617) 248-7240
Number of Pages INCLUDING This Cover Sheet: 4
Re: U.S.S.N 09/256,156
Atty Docket No. LEX-003 (4006/14)

Comments: Certificate of Facsimile Transmission and Supplemental Amendment attached.

2613821_1

This facsimile is subject to attorney-client privilege and contains confidential information intended only for the person(s) named above. If you have received this facsimile in error, please notify us immediately by telephone and destroy the original transmission without making a copy.

Date Sent _____ Time Sent _____

Received from < > at 4/23/03 3:56:14 PM [Eastern Daylight Time]

PATENT
Attorney Docket No. LEX-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gillies et al.
SERIAL NO.: 09/256,156 GROUP NO.: 1646
FILING DATE: February 24, 1999 EXAMINER: Murphy, J.F.
TITLE: ENHANCING THE CIRCULATING HALF-LIFE OF ANTIBODY-
BASED FUSION PROTEINS

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence, and any document(s) referred to as attached hereto, is/are being transmitted to the United States Patent and Trademark Office, Facsimile No. (703) 746-5164 on this 23rd day of April 23, 2003.


Kristin A. Porcu

Attached hereto is/are:

1. Supplemental Amendment (2 pages).

2613820_1

24/E
Dmt
424-03PATENT
Atty. Docket No. LEX-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Gillies et al.
SERIAL NUMBER: 09/256,156 GROUP NUMBER: 1646
FILING DATE: February 24, 1999 EXAMINER: Murphy, J. F.
TITLE: ENHANCING THE CIRCULATING HALF-LIFE OF
ANTIBODY-BASED FUSION PROTEINS

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL AMENDMENT

Sir:

Applicants respectfully request that the following Supplemental Amendment be entered prior to further examination of the present application. Applicants believe that no extension-of-time, or related fee, is required for entry of this paper. However, if any fees are due for this submission, the Director is hereby authorized to charge the required fee to Deposit Account No. 20-0531.

Applicants add new claim 28. Accordingly, after entry of this Supplemental Amendment, claims 1-4, 6-13, 27 and 28 will be pending for examination.

AMENDMENTSTo the Claims

Please add claim 28 to read as follows.

28. (New) The antibody-based fusion protein of claim 13, wherein said interleukin receptor is selected from the group consisting of interleukin-1 and interleukin-4 receptors.

E1